Today, Iovance reported second quarter 2026 financial results and corporate updates, capping a quarter of strong momentum across the business. Read the press release: https://lnkd.in/gji25Q9F We will host a live audio webcast at 8:30 a.m. ET today — join live or listen to the replay: https://lnkd.in/gAiVb5D6
Iovance Biotherapeutics, Inc.
Biotechnology Research
San Carlos, California 39,175 followers
Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.
About us
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
- Website
-
http://www.iovance.com/
External link for Iovance Biotherapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Carlos, California
- Type
- Public Company
- Founded
- 2007
- Specialties
- Immuno Oncology, Autologous Cell Therapy, Tumor Infiltrating Lymphocytes (TIL), Novel Cancer Immunotherapies, and cell therapy
Locations
Employees at Iovance Biotherapeutics, Inc.
Updates
-
Join us on Thursday, August 6, 2026, at 8:30 a.m. ET for our Q2 2026 conference call and live audio webcast, where we'll discuss our quarterly business performance and recent company developments. Register to listen live: https://lnkd.in/ggtrK35E. The live and archived webcast will also be available in the Investors section of our website: IR.Iovance.com.
-
-
This Fourth of July, we’re celebrating freedom and sun safety. ☀️About 9 in 10 skin cancers are linked to UV exposure. A few simple habits can make a big impact as you enjoy the holiday outdoors: 🧴 Wear broad-spectrum sunscreen, SPF 30+ 🧢 Cover up with a hat, sunglasses, and sun-protective clothing ⛱️ Seek shade during peak midday rays 🚫 Skip the tanning beds Enjoy the fireworks—and protect the skin you’re in. 🎆 Learn more at ➡️ Melanoma Research Alliance #MelanomaAwareness #SunSafety #SkinCancerPrevention #FourthOfJuly
-
-
Rare doesn't mean forgotten. This #SarcomaAwarenessMonth, we're shining a light on #sarcoma and our commitment to advance personalized cell therapies for patients. Knowledge changes outcomes. Share this post to help more people recognize sarcoma and why early detection matters. #Celltherapy
-
-
What if preparing for the next step in a melanoma patient’s care doesn’t have to wait until they run out of options? Medical oncologist Dr. Sajeve Thomas is sharing why earlier planning may change the treatment journey for patients with BRAF-mutated melanoma who have progressed on initial therapy. As he puts it, sometimes innovation isn’t only a new therapy — it’s a better process. Read Dr. Thomas’s full perspective ⬇️ #Melanoma #CellTherapy #TILTherapy #Oncology https://lnkd.in/gvgyeMgf
-
Pride isn't just a month. It's a mindset. At Iovance, we're rewriting what's possible for patients facing cancer. That takes bold thinking. Diverse lived experiences. And a culture where everyone belongs — not in theory, but in practice. To our LGBTQ+ colleagues, community members, and allies: your authenticity makes us stronger. Happy Pride.🌈#PrideMonth #CellTherapy #DiversityInBiotech
-
-
What if your own immune system could help fight cancer? A groundbreaking treatment here at MedStar Georgetown is giving hope to patients with advanced melanoma. Dr. Geoffrey Gibney and his patient Mary Hylton joined FOX 5 DC to share how TIL therapy works and how Mary is now planning her first trip to the West Coast. Watch their conversation here and learn more in the comments.
-
At lovance, cancer survivors are at the heart of everything we do. Today, we're celebrating the strength, resilience, and determination of those who continue to inspire our mission to advance new possibilities for people living with cancer. Join us in honoring survivors, amplifying their stories, and continuing the fight for more time and more hope. #NationalCancerSurvivorsDay
-
-
What a week. Huge thanks to everyone who made #ASCO26 an unforgettable forum for progress in oncology. The energy around cell therapy has never been higher — and Iovance is leading the charge. But we are just getting started. 👇 ✅ IND clearance for IOV-5001 ✅ Approved in Australia ✅ Center stage at Jefferies Healthcare Every step brings us closer to the patients who are counting on us. #TILtherapy #CellTherapy #Oncology #Iovance
-
-
Today, Interim CEO and President, Fred Vogt, PhD, and CFO Corleen Roche will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference at 1:25 p.m. ET. Register for the live webcast or replay here: https://lnkd.in/eDZ5prYa
-